/Investor DB

Northpond Ventures — 2021 Investments

18 investments dated 2021 · listed companies and verified rows first · show all

Camp4camp4tx.comin𝕏Series A · Jun 2021 · $45M

Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.

AI & Machine LearningBiotech

Leonard Zon(Founder)Richard Young(Founder)

BoardChristopher Walsh, MD, PhD(Scientific Advisor)

Co-investors5AM VenturesAndreessen HorowitzEnavate SciencesFlucas Ventures

Culture Biosciencesculturebiosciences.comin𝕏Series B · Oct 2021 · $80M

Culture Biosciences operates bioreactors as a service for biotech companies, running fermentation experiments and developing manufacturing processes for customers that engineer organisms to produce therapeutics, materials, fuels, and foods.

AI & Machine LearningBiotechCloud ComputingFoodTechHealthtechNew MaterialsSan Francisco, US

Will Patrick(CEO)inMatt Ball(CTO)inJonathan Meed(Senior Software Engineer)Satshabad Khalsa(Software Engineer)Andre Castillo(Director of Hardware Operations, Manufacturing and Quality)Fre Tachea(Director of Fermentation)

Co-investorsCompoundCultivian Sandbox VenturesDCVC (Data Collective)GRIDS CapitalHemisphere Ventures LLCSynthesis Capital+20 more

Current Healthcurrenthealth.comin𝕏Series B · Apr 2021 · $43Macquired by Best Buy

Current Health builds FDA-cleared clinical technology and infrastructure that enables acute and complex care—including advanced therapies like CAR-T, bispecifics, and cell and gene therapies—to be delivered safely in ambulatory and home settings.

AI & Machine LearningDigital HealthHealthtechMedical DevicesEdinburgh, US

Christopher McGhee(Founder)in

Co-investorsLRVHealthMMC VenturesOSF VenturesPerot JainSection 32

Encodiaencodia.comSeries C · Jan 2021 · $75MDefunct

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsARCH Venture PartnersDecheng CapitalAlexandriaDeerfield Management CompanyGV (Google Ventures)Nan Fung Life Sciences

ISOLERE BIO INCisolerebio.cominSeed · May 2021 · $7M

Isolere Bio develops affinity-based reagents and purification platforms for concentrating and purifying viral vectors used in gene therapy, including adeno-associated viruses and lentiviruses.

Advanced ManufacturingBiotechDeep TechNew MaterialsResearch Triangle Park, US

Michael LaBreck(Co-founder)Michael Dzuricky(Director of Advanced R&D)

Kytopenkytopen.cominSeries A · Sep 2021 · $30M

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.

BiotechDeep TechHardwareCambridge, US

Cullen Buie(Founder; Board Observer)inPaulo Garcia(Founder)inMichael Chiu(Chief Executive Officer)in

BoardPaxton Major(Director)inAnn DeWitt(Director)inPaul Wotton(Director)

Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsTelegraph Hill Partners+2 more

Outcomes4Meoutcomes4me.comin𝕏Series A · Apr 2021 · $12M

Outcomes4Me is an AI-driven patient platform that integrates with NCCN clinical oncology guidelines to provide personalized cancer care guidance, treatment options, clinical trial recommendations, and genetic testing information.

AI & Machine LearningDigital HealthHealthtechCambridge, US

Maya R. Said(Founder and CEO)inOsama Rahma(Founder)inMaya R. Said, Sc.D.(Founder and CEO)

BoardAndrea Jackson(Director)inDavid Fleshman(Director)David Auckland(Director)

Co-investorsAsset Management CompanyHealthX VenturesSierra VenturesAsset Management Ventures

Scitarascitara.comin𝕏Series A · Jan 2021 · $5M

Scitara provides cloud-based integration and data management software for scientific laboratories, enabling connection of lab instruments and applications into a unified environment with AI-powered analytics.

AI & Machine LearningBiotechData & InfrastructureSaaSMarlborough, US

Ajit Nagral(CEO & Chairman)inGeoff Gerhardt(Executive Officer, Promoter)inVinayak Purohit(Executive Officer)in

BoardCharles M. Hazard, Jr.(Director)inAndrea Jackson(Director)inRohit Khanna(Director)

Co-investorsFlybridge Capital Partners

Simbiosyssimbiosys.comin𝕏Series A · Oct 2021 · $15M

SimBioSys builds AI-powered 3D visualization and diagnostic technology that models tumors as "digital twins" to support individualized cancer treatment planning.

AI & Machine LearningBiotechDigital HealthMedical DevicesChicago, US

Joe Peterson(Co-founder)John Cole(Co-founder)Tushar Pandey(Co-founder)inStacey Stevens(Executive Officer, Director)in

BoardVikram Chaudhery(Director)inLucy Coassin(Director)

Co-investorsAV8 VenturesGenoa VenturesKleinmuntz AssociatesXcellerant VenturesGENERAL INCEPTION

Slingshot Biosciencesslingshot.bioinSeries A · May 2021 · $23M

Slingshot Biosciences makes synthetic cell mimics used as standardized reference controls for flow cytometry and cell-based assays.

Emeryville, US

Jeff Kim(Founder)inAdam Wieschhaus(Director)Ronald J. Silberman(Director)

BoardCorey Ritter(Director)in

Co-investorsARCH Venture PartnersAnterra Capital

Sound Agriculturesound.agin𝕏Sep 2021 · $45M

Sound Agriculture develops bio-inspired soil and crop solutions that reduce synthetic fertilizer use and improve nutrient efficiency for growers.

AgTechCleantechClimate TechImpact & Social Good

Eric Davidson, PhD(Co-Founder)Travis Bayer, PhD(Co-Founder)Paul Beck(Chief Executive Officer)

Co-investorsCavallo VenturesFall Line CapitalMission BiocapitalLeaps by BayerS2G InvestmentsSyngenta Group Ventures

Stratus Therapeuticsstratustx.comSeries A · Sep 2021 · $72M

Developing off-the-shelf hematopoietic stem cell therapies for severe diseases.

Co-investorsOrbiMedAisling Capital

Stridebiostridebio.cominSeries B · Mar 2021 · $82M

StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.

BiotechHealthtechDurham, US

Aravind Asokan(Director)inMavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)inPatrick Ritschel(Executive Officer, Director, Promoter)

Co-investorsHatteras Venture PartnersPontifax Venture CapitalAbingworthDe Novo Ventures

Syapsesyapse.comFeb 2021 · $68M

Palo Alto, US

Jonathan Hirsch(Founder)Glenn Winokur(Founder)Tony Loeser(Founder)

BoardJohn Kuelper(Director)inChamath Palihapitiya(Director)inGary Kurtzman, M.D.(Director)

Co-investorsAscension VenturesGE VenturesSocial Capital Partnership

Torus Biosystemstorus.bioinSeries A · May 2021 · $25M

BiotechCambridge, US

Shawn Marcell(Executive Officer, Director)Ben Linden(Executive Officer)inDavid Yu Zhang(Director)Peng Yin(Director)

BoardAdam Wiechhaus(Director)

Co-investorsIllumina Ventures

Vestaron, Inc.vestaron.cominSeries B · Feb 2021 · $18M

Vestaron develops peptide-based insecticides derived from naturally-occurring peptides such as those found in spider venom, produced through fermentation, offering new modes of action for crop protection.

AgTechBiotechCleantechClimate TechNew MaterialsKalamazoo, US

Glenn King(Founder)inJuan Estupinan(Executive Officer, Director)inDawn de los Santos(Executive Officer)inRobert Kennedy(Executive Officer)Nancy Newman(Executive Officer)inJohn C. Sorenson(Executive Officer, Director)

Co-investorsArgonautic VenturesCavallo VenturesCultivian Sandbox VenturesEndeavor8iSelect FundMichigan Capital Network+4 more

VieCureviecure.comSeries A · Apr 2021 · $25M

Co-investorsSocium Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Hawthorne Effect

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.